期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CALR基因突变在经典骨髓增殖性肿瘤中的生物学特征及临床意义 被引量：6

Biological characteristics and clinical implications of CALR mutations in classic myeloproliferative neoplasms
原文传递
导出
摘要 CALR基因突变是新发现的经典骨髓增殖性肿瘤（MPN）的生物学标志,其在原发性血小板增多症和原发性骨髓纤维化患者中的发生率为20％～ 35％,与特定临床特征和良好预后相关.文章对CALR基因突变在经典MPN中的生物学特征和临床意义进行介绍. CALR mutations are discovered in classic myeloproliferative neoplasms （MPN） as a new biomarker very recently.CALR mutations occur in about 20 %-35 % essential thrombocythemia and primary myelofibrosis and are associated with some clinical features and favorable prognostic impact.This article reviews biological characteristics and clinical implications of CALR mutations in classic MPN.
作者 惠吴函 田丁
机构地区 首都医科大学宣武医院血液科
出处 《白血病．淋巴瘤》 CAS 2015年第7期420-423,427,共5页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金（81400094） 首都医科大学基础-临床科研合作基金（1140170021）
关键词 骨髓增殖性肿瘤 CALR基因突变 Myeloproliferative neoplasms CALR mutations
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献40

  • 1Baxter E J, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [ J ]. Lancet, 2005, 365 ( 9464 ) : 1054-1061.
  • 2James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera [ J ]. Nature, 2005, 434 ( 7037 ) : 1144-1148.
  • 3Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L! K mutation in essential thrombocythemia [ J ]. Blood, 2008, 112 ( 3 ) : 844-847.
  • 4Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms : JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 [ J 1. Leukemia, 2010, 24 ( 6 ) : 1128-1138.
  • 5Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms [ J ]. Leukemia, 2011, 25 ( 7 ) : 1217-1219.
  • 6Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms [ J]. Blood, 2010, 116 ( 6 ) : 988-992.
  • 7Ernst T, Chase A J, Score J, et al. Inactivating mutations of the histone methyhransferase gene EZH2 in myeloid disorders [ J ]. Nat Genet, 2010, 42( 8 ) : 722-726.
  • 8Nangalia J, Massie CE, Baxter E J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 [ J ]. N Engl J Med, 2013, 369 ( 25 ) : 2391-2405.
  • 9Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013, 369 (25): 2379-2390.
  • 10Michalak M, Groenendyk J, Szabo E, et al. Calreticulin, a multi- process calcium-buffering chaperone of the endoplasmic reticulum [ J ]. Biochem J, 2009, 417 ( 3 ) : 651-666.

同被引文献42

  • 1应逸,陈建兰,王汉平,谢健晋,周薇,陈小卫,陈小燕.急性髓细胞白血病NPM1和FLT3-ITD突变检测临床意义分析[J].中华肿瘤防治杂志,2013,20(2):121-124. 被引量：6
  • 2James C, Ugo V, Le Cou6dic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [ J ]. Nature, 2005, 434 ( 7037 ) : 1 144-1148.
  • 3Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [ J ]. Lancet, 2005, 365 ( 9464 ) : 1054-1061.
  • 4Levine RL, Wadleigh M, Cools J, et al. Activiting mutation in thetyrosine kinase JAK2 polycythaemia vera, essential thrombythemia, and myeloid metaplasia with myelofibrosis [ J ]. Cancer Cell, 2005, 7 ( 4 ) : 387-397.
  • 5Kralavics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorde [ J]. N Engl J Med, 2005, 352( 17 ) : 1779-1790.
  • 6Harrison C, Kiladjian JJ, A1-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis [ J]. N Engl J Med, 2012, 366 (9): 787-798.
  • 7Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? [ J ]. Hematology Am Soc Hematol Educ Program, 2014, 2014 ( 1 ) : 268-276.
  • 8Nangalia J, Green TR. The evoloving gemomic landscape of myeloproliferative neoplasms [ J ]. Hematology Am Soe Hematol Educ Program, 2014, 2014 ( 1 ) : 287-296.
  • 9Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013, 369( 25 ): 2379-2390.
  • 10Geyer HL, Mesa RA. Therapy for MPNs:when,which agent,and how? [ J ]. Hematology Am Soc Hematol Educ Program, 2014, 2014 ( 1 ) : 277-286.

引证文献6

二级引证文献14

白血病．淋巴瘤
2015年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部